NEW YORK (GenomeWeb News) – Accelerate Diagnostics has filed a shelf registration to publicly offer from time to time up to $150 million of securities.

In a Form S-3 filed with the US Securities and Exchange Commission on Wednesday, the company said that it may offer common stock, preferred stock, debt securities, warrants, and/or units in combination. Net proceeds from any offering will go toward general corporate purposes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.